Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
28.15B
Market cap28.15B
Price-Earnings ratio
21.82
Price-Earnings ratio21.82
Dividend yield
Dividend yield
Average volume
1.01M
Average volume1.01M
High today
$192.44
High today$192.44
Low today
$186.62
Low today$186.62
Open price
$187.28
Open price$187.28
Volume
1.40M
Volume1.40M
52 Week high
$202.41
52 Week high$202.41
52 Week low
$110.04
52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $191.82, giving the company a market capitalization of 28.15B. It carries a P/E multiple of 21.82.

On 2026-03-01, Biogen(BIIB) stock moved within a range of $186.62 to $192.44. With shares now at $191.82, the stock is trading +2.8% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 1.4M, compared to an average daily volume of 1.01M.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

Simply Wall St 2d
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment

Biogen is advancing its Alzheimer’s treatment pipeline, with mid year clinical results for its BIIB080 drug candidate expected in the coming months. The compan...

Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment

Analyst ratings

54%

of 37 ratings
Buy
40.5%
Hold
54.1%
Sell
5.4%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.